Skip to main content

Fangzhou and Tenry Pharmaceutical Forge Strategic Partnership to Advance AI-Powered Chronic Disease Care

Written by Customer Service on . Posted in Public Companies.

SHANGHAI, May 14, 2026 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, and Shanghai Tenry Pharmaceutical Co., Ltd. (“Tenry Pharmaceutical”) have entered into a strategic partnership at the 92nd PHARMCHINA in Shanghai, marking a significant step toward advancing AI-powered chronic disease management and broader support across the patient journey.

The partnership will combine technological innovation and operational expertise to build a more efficient and patient-centered chronic disease service model, supporting the industry’s shift from a narrow focus supplying medication towards more comprehensive patient support.

Fangzhou and Tenry Pharmaceutical Forge Strategic Partnership

Fangzhou and Tenry Pharmaceutical Forge Strategic Partnership

As part of the collaboration, Tenry Pharmaceutical’s innovative GLP-1 therapy, Paidakang® (派达康®, injectable vipeglutide), is expected to make its nationwide debut through Fangzhou’s Internet hospital platform.

With years of experience in chronic disease management, Fangzhou has built an “AI+H2H (Hospital to Home)” intelligent healthcare model supported by a robust service ecosystem and advanced AI capabilities. Powered by its proprietary Xingshi Large Language Model, the Company is further strengthening its role as a trusted, long-term health service partner by applying tools such as AI Medication Assistant, AI Doctor Assistant and AI Health Manager to improve the quality and efficiency of chronic disease care.

As a key innovative therapy in Tenry Pharmaceutical’s commercial portfolio, Paidakang® focuses on the treatment of type 2 diabetes and metabolic disorders, aiming to provide patients with a treatment option that combines efficacy, safety, and convenient dosing.

This strategic alliance brings together Fangzhou’s AI-driven service capabilities and Tenry Pharmaceutical’s innovative drug expertise to expand chronic disease management and full-cycle health management in metabolic diseases. By combining advanced digital tools with professional care, the partnership aims to make high-quality medical resources more accessible to patients nationwide and better support their long-term health management needs.

This collaboration marks an important milestone in the companies’ shared commitment to advancing chronic disease management and supporting the Healthy China 2030 initiative. Going forward, both parties plan to deepen resource integration, broaden AI-powered applications and explore additional service scenarios under the “AI+Chronic Disease Service” model, delivering professional, accessible and long-term care support to patients across China.

About Paidakang® (PB-119)

Paidakang® (PB-119) was developed by PegBio Co., Ltd. (HKEX: 02565), targeting type 2 diabetes and metabolic disorders. In clinical studies, patients on the drug achieved sustained glycemic control over 52 weeks and a lower incidence of gastrointestinal side effects compared with other GLP-1 therapies. Beyond blood glucose control, Paidakang® has also demonstrated potential broader benefits in improving insulin resistance and metabolic status, while offering a simplified dosing regimen that requires no titration. In March 2026, Tenry Pharmaceutical secured exclusive commercialization rights for Paidakang® in mainland China.

About Fangzhou Inc.

Fangzhou Inc. (HKEX: 06086) is China’s leading online chronic disease management platform, serving 56.4 million registered users and 251,000 physicians (as of December 31, 2025). The Company specializes in delivering tailored medical care and AI-enabled precision medicine solutions. For more information, visit https://investors.jianke.com.

Media Contact

For further inquiries or interview requests, please contact:

Xingwei Zhao
Associate Director of Public Relations
Email: pr@jianke.com

Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e3ea81dc-4701-40e3-a0cd-505d016f2c8e

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.